)
Kura Oncology (KURA) investor relations material
Kura Oncology UBS Global Biopharma Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOMZIFTI commercial launch
Q3 launch sales $13.9M, up 53% QoQ; ~150 new patient starts, up 35%; ~420 total prescriptions, up 65%; prescribing accounts grew 40%.
Uptake drivers cited: efficacy, tolerability, once-daily dosing and ability to combine with concomitant medicines and AML therapies.
Physicians’ combination use has grown; most cited use is with venetoclax and azacitidine, with gilteritinib combinations also reported.
Management expects continued commercial growth over the next several quarters; estimated relapsed/refractory market is $350M-$400M, with ~six months of therapy expected.
Management expects combinations may extend treatment duration, while noting this needs to be confirmed as patients continue therapy.
AML combinations and frontline development
ASH plans include relapsed/refractory gilteritinib plus ziftomenib data and frontline quizartinib combinations, including a quizartinib-7+3-ziftomenib quadruplet.
For gilteritinib combination data, management highlighted response rates, durability and transplant outcomes; frontline quizartinib dose escalation reached planned levels without dose-limiting toxicities, with a 100% CRc rate in the reported patients.
KOMET-017 combines intensive and non-intensive frontline cohorts in one protocol; enrollment was tracking in line with expectations.
Initial frontline results are expected in 2028; intensive-chemotherapy accelerated-approval endpoint is MRD-negative CR, with EFS for full approval; non-intensive endpoints are CR and OS, respectively.
Management cited ~44% marrow MRD negativity after 7+3 in NPM1-mutant patients and viewed a 10%-15% improvement as meaningful; for Ven-Aza, it cited 70%-80% CR and a potential meaningful 10%-15% boost.
Darlifarnib development
FDA alignment supports a 40-patient registrational monotherapy trial in HRAS-mutant salivary gland cancer, a high-unmet-need population; management cited response data exceeding expectations for available therapies.
In renal cell carcinoma, the phase I-B cabozantinib combination is expected to complete enrollment in H1 2027, with data in H2 2027; management sees a post-IO second-line opportunity, alongside third-line development.
RCC combination data cited 33%-50% response rates and 13-month PFS, versus third-line benchmarks of 20%-30% response and ~eight-month PFS; response near 50% could support moving directly into second line.
Management estimated a $900M-$1B third-line RCC market and a multi-billion-dollar second-line opportunity, conditional on data and combination strategy.
A pancreatic cancer combination with daraxonrasib is planned; early results may be available in H2 2027. Prior adagrasib combination data were described as encouraging but from small datasets.
Management expects neutropenia rates to decrease with prophylaxis; prior events were described as laboratory findings that did not translate into infections.
- KOMZIFTI sales rose 53% QoQ as clinical programs advanced and financing supported plans through 2028.KURA
Q3 2026 - KO-7246’s durable beta-cell signals support its funded path toward clinical testing.KURA
Investor update - Market leadership in AML, robust pipeline progress, and strong financial runway drive growth.KURA
Morgan Stanley 24th Annual Global Healthcare Conference - KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead.KURA
12th Annual Cantor Fitzgerald Global Healthcare Conference - Strong commercial momentum and advancing late-stage pipeline position for major growth.KURA
Wells Fargo 21st Annual Healthcare Conference - KOMZIFTI posted strong Q2 revenue and market share gains; cash supports key trials through 2028.KURA
Q2 2026 - Darlifarnib plus cabozantinib achieved up to 50% ORR and 13-month PFS in advanced RCC.KURA
Study update - KOMZIFTI's launch drove early revenue, rapid payer adoption, and strong clinical momentum.KURA
Q4 2025 - Positive AML trial, Kyowa Kirin deal, and $727M cash position drive 2025 milestones.KURA
Q4 2024
)
)
)
)
)
)
)
)